4/A//SEC Filing
Najafi Ramin 4/A
Accession 0001437749-12-010839
CIK 0001389545other
Filed
Oct 31, 8:00 PM ET
Accepted
Nov 1, 7:08 PM ET
Size
6.3 KB
Accession
0001437749-12-010839
Insider Transaction Report
Form 4/AAmended
Najafi Ramin
DirectorChief Executive OfficerOther
Transactions
- Award
Option (right to buy)
2012-09-26+65,000→ 679,852 totalExercise: $1.22From: 2013-09-26Exp: 2022-09-26→ Common Stock (65,000 underlying)
Footnotes (3)
- [F1]Twenty-five percent (25%) of the option shares vest and become exercisable on the first anniversary of the date of grant, and the balance of the option shares vest and become exercisable in a series of twelve (12) equal installments upon the completion of each three (3) months beginning September 26, 2013.
- [F2]Original Form 4 filed on 10/12/2012. This amendment is filed to correct the exercise price from $1.29 to $1.22 the closing price on the date the Compensation Committee approved the grant on September 26, 2012.
- [F3]Original Form 4 filed on 10/12/2012. This amendment is filed to correct the grant date from October 10, 2012 to September 26, 2012, the date the Compensation Committee approved the grant. There was a misunderstanding, management thought the grant will be subject to Board ratification at the Board's meeting on 10/10/2012, but the Board agreed that the grant date should be September 26 ,2012, the date of the Compensation Committee meeting.
Documents
Issuer
NovaBay Pharmaceuticals, Inc.
CIK 0001389545
Entity typeother
Related Parties
1- filerCIK 0001410081
Filing Metadata
- Form type
- 4/A
- Filed
- Oct 31, 8:00 PM ET
- Accepted
- Nov 1, 7:08 PM ET
- Size
- 6.3 KB